Loading data for CAPR — first visit, this takes a few seconds.

Capricor Therapeutics, Inc. (CAPR)

NasdaqGS: CAPR · 即時價格 · USD

9.40

+0.12 (1.29%)

收盤價： Sep 04, 2026, 8:00 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	6.97
市值	547M
營收 (ttm)	n/a
淨利（ttm）	-129M
	0.72
	-2.45
	n/a
	-6.36
P/B (ttm)	2.22
P/S (ttm)	0.00
財報日期	Nov 10, 2026

賣價	12
成交量	2,555,651
20 日平均成交量	6,206,793
開盤價	9.40
前收盤價	9.28
當日區間	9.26 - 9.81
52 週範圍	2.96 - 40.37
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Feb 13, 2007

員工 231

證券交易所 NasdaqGS

股票代號 CAPR

網站 https://www.capricor.com

完整的公司簡介

財務表現

Capricor Therapeutics 在 2025 年的營收為 0，較前一年的 22.27M 減少 -100%。淨利為 -105.04M，較前期增加 159.58%。

財務報表

財報驚奇

Capricor Therapeutics 已於 Aug 13, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.7 低於預期 -0.12, 年增 -32.08% 下滑.

下次財報發布

Capricor Therapeutics, Inc. 的下次財報預計於 Nov 10, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

6 天前 · MT Newswires

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and

6 天前 · InvestorsHub

Capricor Therapeutics shares rise 2.5% following August FDA update

Capricor Therapeutics (NASDAQ:CAPR) shares rose 2. 5% in pre-market trading to $10.

6 天前 · Stocktwits

Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision

Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels.

1 週前 · Stocktwits

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.

1 週前 · Insider Monkey

A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path

On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company’s bid to treat cardiomyopa...

第 1 頁，共 2 頁

Capricor Therapeutics, Inc. (CAPR)